This website uses cookies to enhance the user experience.
O

ONCOSYNE AS926 191 942

Research
Limited company
Ullernchausséen 64 0379 OSLO, Norge

ONCOSYNE AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
5 years
since Dec 16, 2020
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
907,348
1 share class
Total number of shareholders
8
6 companies, 2 persons

Financials

Total operating income 2023
1,656,989
NOK
Annual total result 2023
-3,140,780
NOK
Total equity 2023
5,197,039
NOK
Last update: Dec 31, 2024

Management

Board

NameRoleShares
Chairman
38.57 %
indirectly
Board Member-
Board Member
4.57 %
indirectly
Board Member
1.6 %
indirectly
Observer-
Board Member-

Others

NameRoleShares
A
AIDER AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Chairman
38.57 %
indirectly
-
38.57 %
indirectly
Board Member
4.57 %
indirectly
-
3.43 %
indirectly
-
2.51 %
indirectly
-
2.51 %
indirectly
-
2.51 %
indirectly
-
2.29 %
directly
-
2.29 %
indirectly
Board Member
1.6 %
indirectly
Last update: Dec 31, 2024

Ownership

Company shareholders

NameShare classTotal number of sharesShare
K
KAARSTAD SMIER AS
Ordinary shares
350,000
38.57 %
N
NORSKE OMVEIER AS
Ordinary shares
350,000
38.57 %
W
WIBO CONSULTING AS
Ordinary shares
82,939
9.14 %
D
DAEDALUS AS
Ordinary shares
41,470
4.57 %
M
MILLIMEDIA AS
Ordinary shares
31,103
3.43 %
S
SVARTHØI HOLDING AS
Ordinary shares
20,734
2.29 %
Ordinary shares
20,734
2.29 %
Ordinary shares
10,368
1.14 %
Last update: May 24, 2024

Financials

in NOK

Summary

Year202320222021
Total operating income
1,656,989
1,450,000
450,000
Annual Total Result
-3,140,780
-1,280,781
-195,802
Total assets
5,802,910
4,914,137
804,442
Total liabilities
605,872
576,303
185,814
Total equity
5,197,039
4,337,834
618,628

P&L

Year202320222021
Total operating income
1,656,989
1,450,000
450,000
Total operating costs
4,843,673
2,742,102
651,769
Operating result
-3,186,683
-1,292,102
-201,769
Financial income/costs
45,903
11,320
5,967
Profit before tax
-3,140,780
-1,280,781
-195,802
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
-3,140,780
-1,280,781
-195,802

Balance overview

Year202320222021
Total fixed assets
84,859
79,623
0
Total current assets
5,718,052
4,834,514
804,442
Total assets
5,802,910
4,914,137
804,442
Short term debt
605,872
576,303
185,814
Long term debt
0
0
0
Total liabilities
605,872
576,303
185,814
Contributed capital
9,814,402
5,814,417
814,430
Retained earnings
-4,617,363
-1,476,583
-195,802
Total equity
5,197,039
4,337,834
618,628
Total equity and liabilities
5,802,910
4,914,137
804,442

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology